Literature DB >> 11095343

An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities.

D Sorbi1, D B McGill, J L Thistle, T M Therneau, J Henry, K D Lindor.   

Abstract

OBJECTIVE: The role of liver biopsy in the management of patients with nonspecific chronic liver enzyme abnormalities is not well established. The aim of this study is to determine whether liver histology changes the clinical impression formed before liver biopsy and the preliminary management plan.
METHODS: Consenting asymptomatic adult patients with persistent (> or = 6 months) liver test abnormalities were enrolled. Patients with a strong suspicion for a specific liver disease were excluded. A presumptive diagnosis and a preliminary management plan were documented before a liver biopsy. After the liver biopsy, the patients were reassessed to determine the effect of the biopsy on the diagnosis and management plan.
RESULTS: A total of 36 patients were enrolled: 15 men and 21 women, with a median age of 51 yr. The prebiopsy diagnoses were nonalcoholic steatohepatitis (24), autoimmune hepatitis (3), primary biliary cirrhosis (2), primary sclerosing cholangitis (2), and miscellaneous (5 patients). The liver biopsy changed the diagnosis in 14% of cases. Lifestyle recommendations were not significantly altered by the biopsy. The liver biopsy affected the frequency of liver test monitoring in 13 patients (36%). Treatment recommendations were affected in 12 cases, 10 of whom were offered investigational therapy.
CONCLUSIONS: Although a liver biopsy may help to definitively establish the final diagnosis in patients, the results alter the presumptive prebiopsy diagnosis infrequently, and no proven therapy exists for the vast majority of these patients. Therefore, the risks and benefits of a liver biopsy should be carefully weighed, especially in settings in which investigational therapies are unavailable.

Entities:  

Mesh:

Year:  2000        PMID: 11095343     DOI: 10.1111/j.1572-0241.2000.03293.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  Liver biopsy: when, how, by whom, and where?

Authors:  D B McGill
Journal:  Curr Gastroenterol Rep       Date:  2001-02

2.  To perform or not to perform liver biopsy-that is the question.

Authors:  R W Chapman
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 3.  Best practice in primary care pathology: review 5.

Authors:  W S A Smellie; J Forth; S Ryder; M J Galloway; A C Wood; I D Watson
Journal:  J Clin Pathol       Date:  2006-04-27       Impact factor: 3.411

Review 4.  Treatment of fibrosis in nonalcoholic fatty liver disease.

Authors:  Maarouf A Hoteit; Frank A Anania
Journal:  Curr Gastroenterol Rep       Date:  2007-03

5.  Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.

Authors:  Agostino Colli; Alice Colucci; Silvia Paggi; Mirella Fraquelli; Sara Massironi; Marco Andreoletti; Vittorio Michela; Dario Conte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

6.  Liver biopsy in a district general hospital: changes over two decades.

Authors:  Wing-Kin Syn; Caroline Bruckner-Holt; Adam Farmer; Sarah Howdle; Jeffrey Bateman
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

Review 7.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 8.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Paul Angulo; Keith D Lindor
Journal:  CMAJ       Date:  2005-03-29       Impact factor: 8.262

Review 9.  Controversies in liver biopsy: who, where, when, how, why?

Authors:  Lawrence S Friedman
Journal:  Curr Gastroenterol Rep       Date:  2004-02

Review 10.  Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.

Authors:  David E Kleiner; Hala R Makhlouf
Journal:  Clin Liver Dis       Date:  2015-12-28       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.